

Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full deal details and analysis.
You can purchase shares of Personalis (NASDAQ:PSNL) through any online brokerage.
Other companies in Personalis’s space includes: Thermo Fisher Scientific Inc (NYSE:TMO), Danaher Corp (NYSE:DHR), Waters Corp (NYSE:WAT), Agilent Technologies Inc (NYSE:A) and IQVIA Holdings Inc (NYSE:IQV).
Personalis has a consensus price target of $12.65.
The stock price for Personalis (NASDAQ: PSNL) is $14.01 last updated November 20, 2026 at 6:45 PM EST.
There are no upcoming dividends for Personalis.
Personalis does not have any upcoming earnings scheduled.
There is no upcoming split for Personalis.
Personalis is in the Health Care sector and Life Sciences Tools & Services industry. They are listed on the NASDAQ.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis...